Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25329973 | 0.87 | MTNR1A (0.42) | GRM2MTNR1AMTNR1BFPR1FPR2 | |
| SCHEMBL27057488 | 0.86 | MTNR1A (0.54) | EPHX2MTNR1AMTNR1BRORC | |
| SCHEMBL25330144 | 0.83 | TEAD1 (0.46) | GRM2MTNR1AMTNR1BFPR1FPR2 | |
| SCHEMBL27057237 | 0.82 | CCRL2 (0.39) | EPHX2MTNR1AMTNR1BRORCCCRL2 | |
| SCHEMBL30767959 | 0.82 | CCRL2 (0.39) | EPHX2MTNR1AMTNR1BRORCCCRL2 | |
| SCHEMBL27057835 | 0.81 | SYK (0.38) | EPHX2GRM2RORCSYKCCRL2 | |
| SCHEMBL27057709 | 0.80 | EPHX2 (0.44) | EPHX2GRM2RORCSYKCCRL2 | |
| SCHEMBL25815814 | 0.80 | SLC6A2 (0.39) | GRM2FPR1FPR2 | |
| SCHEMBL25815594 | 0.79 | SCN9A (0.49) | EPHX2MTNR1AMTNR1BRORC | |
| SCHEMBL30767952 | 0.78 | RORC (0.39) | GRM2RORCSYKCCRL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | EPHX2 2674/4885GRM2 4221/4885MTNR1A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.